Brii Bio’s funding to Columbia comes in the form of an unrestricted grant to facilitate creating a framework for the formation of strategic collaborations in areas of complementary
The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate -040 trial. Around
IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT
The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has advanced on
The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19). These fully
The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still suffering from the
The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are not
NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the
Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most
The company will inform the members of the US Congress regarding the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for the treatment of high-risk individuals with COVID-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.